The partner this time is Astellas Pharma of Toyko, which signed a deal to pay $120 million over the next five years - including $20 million upfront - for a non-exclusive license for the technology

Ltd. (now part of Tokyo-based Astellas Pharma Inc.) The company also has preclinical programs in rheumatoid arthritis and asthma.

Astellas Pharma US Inc

with Astellas Pharma US Inc., a subsidiary of Tokyo-based Astellas Pharma Inc

Eligard is sold by Astellas Pharma Inc., of Tokyo, from which MediGene is entitled to a milestone payment of an undisclosed amount

Eligard is sold by Astellas Pharma Inc., of Tokyo, from which MediGene is entitled to a milestone payment of an undisclosed amount

The NDA filing triggers a milestone payment of $31 million from Theravance's partner, Astellas Pharma Inc., of Tokyo

Cardiome Pharma Corp., of Vancouver, British Columbia, and Astellas Pharma US Inc., of Deerfield, Ill., said the FDA accepted for review their new drug application for the intravenous formulation of vernakalant hydrochloride, an investigational product for the acute conversion of atrial fibrillation

Santa Clara, Calif.-based XenoPort exclusively licensed to GSK worldwide rights to XP13512, with the exception of certain Asian territories licensed in 2005 to Tokyo-based Astellas Pharma Inc

Partnered preclinical programs include a compound for atrial fibrillation, with Bristol-Myers Squibb Co., of New York, and leads for memory disorders, with Astellas Pharma Inc., of Tokyo

Astellas Pharma U.S. Inc. (PK:ALPMF) Vernakalant hydrochloride Intravenous formulation For the acute conversion of atrial fibrillation Resubmitted the NDA (12/19) Encysive Pharmaceuticals Inc. (ENCY) Thelin Sitaxsentan sodium Pulmonary arterial hypertension FDA informed the company that its response to the July 24 approvable letter is not complete (12/14

Company* (Country; Symbol) Product Description Indication Status (Date) AUTOIMMUNE ChemoCentryx Inc.* Traficet-EN Orally active, anti- inflammatory agent that targets CCR9 Crohn's disease Phase II data complement earlier results showing improved clinical endpoints (12/4) Genmab A/S (Denmark; CSE:GEN) HuMax-CD20 Ofatumumab; a fully human antibody targeted at the CD20 molecule found in the cell membrane of B cells Rheumatoid arthritis Phase II data of the first 100 patients showed a

An intravenous formulation of the drug for the acute conversion of AF demonstrated promising results in two pivotal studies, which led to the submission of an NDA by partner Astellas Pharma US in April 2006, but was followed by a refusal to file letter in May from the FDA citing "inconsistencies and omissions in the database...Astellas, a subsidiary of the Tokyo-based Astellas Pharma Inc., holds North American rights to the intravenous formulation of vernakalant

January | February | March | April | May | June | July | August | September | October | November | December December - 2007 Biotech Company Pharma Company Type/Product Area Terms/Details Abeome Corp. Millipore Corp. Exclusive worldwide marketing and distribution agreement for rights to Abeome's stem cell monoclonal antibody Human Embryonic Stem Cell Antigen-1 Abeome received an undisclosed up-front payment and also will receive royalties on sales by Millipore Addex

TOTAL: $M54.0 Year to Date: $589.33M Company (Symbol)#* Partner (Country) Amt. (M) Triggering Event Details (Date) Cardiome Pharma Corp. (Canada; CRME) Astellas Pharma US Inc. $10 Milestone payment Triggered by Astellas' resubmission of the NDA with the FDA seeking approval of the intravenous formulation of vernakalant hydrochloride for the acute conversion of atrial fibrillation (12/18) Cerus Corp. (CERS) BioOne Corp. (Singapore) $5 Milestone payment Triggered by CE mark regulatory

Cardiome Pharma Corp., of Vancouver, British Columbia, said its co-development partner, Astellas Pharma U.S. Inc., of Deerfield, Ill., resubmitted the new drug application to market the intravenous formulation of vernakalant hydrochloride for the acute conversion of atrial fibrillation

The product is partnered with Tokyo's Astellas Pharma Inc

CV Therapeutics Inc., of Palo Alto, Calif., and Astellas Pharma US Inc., of Deerfield, Ill., said the second of two Phase III studies of regadenoson met its primary endpoint by showing that myocardial perfusion imaging (MPI) studies conducted with regadenoson were comparable to MPI studies conducted with Adenoscan (adenosine injection

Eligard, a palliative treatment for advanced prostate cancer, will be marketed by QLT's European partner, Tokyo-based Astellas Pharma Inc